Downregulation of PART1 Inhibits Proliferation and Differentiation of Hep3B Cells by Targeting hsa-miR-3529-3p/FOXC2 Axis

Table 1

Clinical information analysis of the significance of PART1 expression in liver cancer.

Clinicopathological parameter	PART1 expression
			Lower expression (%)	High expression (%)	value
Gender	Male	24	12	12	1.000
	Female	6	3	3
Age	≤65	19	8	11	0.2557
	>65	11	7	4
Tumour size	<5 cm	15	11	4	0.0106
	≥5 cm	15	4	11
Tumour metastasis	+	12	5	7	0.4561
	−	18	10	8
BCLC stage	B	14	4	10	0.0281
	C	16	11	5
TNM stage	I–II	14	4	10	0.0281
	III–IV	16	11	5

Note. Compared with control group, ; .